

***Information for Pharmacists***

**Claims Submission Procedure – Inflectra**  
***Effective April 1, 2025***

**Please include this Procedure in your Drug Programs Information Network (DPIN) Manual under Section 4: Claims Submission.**

**\*\*Pharmacies do NOT receive drug interaction information when submitting claims using PINs. Please review all claims carefully prior to submitting\*\***

- DIN 02419475 will be commercially available as both Inflectra and Remdantry branded products until September 30, 2025.
- Due to this name change, the department has assigned PIN 66128531 to Inflectra.
- **Effective April 1, 2025, while DIN 02419475 is available as both Inflectra and Remdantry branded products, claims must be submitted to DPIN as follows:**
  - Inflectra (DIN 02419475) – using PIN 66128531
  - Remdantry (DIN 02419475) – using DIN 02419475
- Exception Drug Status (EDS) coverage for PIN 66128531 will be provided to clients with existing EDS coverage for infliximab.
- After September 30, 2025, Inflectra branded product will no longer be available on the Canadian market and PIN 66128531 will be expired.